Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody
Author: Staudacher, A.H.
Liapis, V.
Tieu, W.
Wittwer, N.
Brown, M.P.
Citation: Journal of Controlled Release, 2020; 327:779-787
Publisher: Elsevier
Issue Date: 2020
ISSN: 0168-3659
Statement of
Alexander H. Staudacher, Vasilios Liapis, William Tieu, Nicole L. Wittwer, Michael P. Brown
Abstract: APOMAB (chDAB4) is a dead tumour cell-targeting antibody which has been used preclinically as a diagnostic agent and therapeutically as a radioimmunotherapy and antibody drug conjugate (ADC). However, little is known of the intra-tumour processing of chDAB4 when bound to dead tumour cells. In this study we examine the role of macrophages in the in vitro and in vivo processing of radiolabelled chDAB4 and a chDAB4 ADC. We found that chDAB4 binds to macrophages in vitro, resulting in the killing of macrophages when using the ADC, chDAB4-SG3249. Free drug released by the macrophage processing of chDAB4-SG3249 could result in killing of 'bystander' Lewis lung (LL2) carcinoma cells. Furthermore, macrophages phagocytosed chDAB4-bound dead LL2 cells and were killed when they phagocytosed chDAB4-SG3249-bound dead LL2 cells in vitro. In vivo, we found markedly different tumour retention of chDAB4 in the LL2 tumour model depending on whether it was radiolabelled with a residualising radionuclide (⁸⁹Zr), which is retained intracellularly, or a non-residualising radionuclide (¹²⁴I), which can diffuse out of the cell. This prolonged retention of ⁸⁹Zr vs¹²⁴I indicated intra-tumoral processing of chDAB4 in vivo. The tumour uptake of 89Zr-chDAB4 was reduced after macrophage depletion, which also reduced the efficacy of the chDAB4 ADC in vivo. This study shows that macrophages can process chDAB4 and chDAB4 ADC in vitro and shows the importance of tumour-associated macrophages in the tumour retention of chDAB4 and the efficacy of chDAB4 ADC in vivo.
Keywords: La/SSB; APOMAB; antibody drug conjugate; PBD dimer; bystander killing; macrophages; zrconium-89; iodine-124
Rights: © 2020 Elsevier B.V. All rights reserved.
DOI: 10.1016/j.jconrel.2020.09.027
Grant ID:
Published version:
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.